Amgen is deepening its collaboration with Amazon Web Services (AWS) to pioneer generative artificial intelligence (generative AI)-based solutions for drug discovery, development, and manufacturing efficiency.
Together, Amgen and AWS are experimenting with generative AI and machine learning technologies, exploring solutions not only for research and development but also for operations and commercial lines of business, utilizing services like Amazon Bedrock and Amazon SageMaker JumpStart. The biotech plans to harness AWS's global infrastructure and advanced services for a new assembly and packaging site in Ohio.
This new digital data and analytics platform, powered by AWS, will leverage the latest digital and robotic technology to enhance operational efficiency and sustainability.
Amgen's strategic use of Amazon SageMaker, a fully managed service for machine learning (ML) models, aims to minimize manual intervention, improve safety through AI, sensors, and machine vision systems, and predict equipment failures in real time.